Study of IW-1701, A Stimulator of Soluble Guanylate Cyclase (sGC), in Patients With Type I or II Achalasia

Summary

The objectives of this study are as follows: In participants with primary Type I or II achalasia, following a single 5-mg dose of olinciguat (IW-1701), * To assess the safety and tolerability * To determine the effects on measures of esophageal function by high-resolution impedance manometry (HRIM) * To determine the pharmacokinetic (PK) parameters

Timeline

Start

2017-04-06

Primary completion

2018-05-01

Completion

2018-05-01

Outcome

Outcome not reported

Stopped (Enrollment): “The study was prematurely terminated due to enrollment challenges.”

Drugs

Indications